Serclutamab

• CAT Number: I040369
• CAS Number: 2140172-41-2
• Purity: ≥95%

Serclutamab(CAT: I040369) is a monoclonal antibody designed to target and inhibit AXL, a receptor tyrosine kinase implicated in tumor growth, metastasis, immune evasion, and resistance to therapy. By blocking AXL signaling, Serclutamab disrupts key oncogenic pathways, including those involved in epithelial-mesenchymal transition (EMT), angiogenesis, and survival signaling. It is being developed as a therapeutic candidate for various solid tumors, including non-small cell lung cancer (NSCLC) and other malignancies characterized by AXL overexpression. Serclutamab enhances antitumor immune responses and may synergize with other treatments such as immune checkpoint inhibitors or chemotherapy, offering a targeted approach to overcoming tumor aggressiveness and resistance.